Longbio Pharma (Suzhou) Co (HKSE:01779) EBITDA Margin %: 0.00% (As of Dec. 2025)


HKSE:01779 Longbio Pharma (Suzhou) Co Ltd HKSE:01779
10 GF Score
Price HK$157.20
View Full Analysis

What is Longbio Pharma (Suzhou) Co EBITDA Margin %?

Longbio Pharma (Suzhou) Co HKSE:01779 +3.63% 10 EBITDA Margin % is 0.00% as of Dec. 2025. GuruFocus rates HKSE:01779 with a GF Score™ of 10/100. Among 945 Biotechnology companies, Longbio Pharma (Suzhou) Co ranks worse than 105820% on this metric.

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Longbio Pharma (Suzhou) Co's EBITDA for the six months ended in Dec. 2025 was HK$-166.95 Mil. Longbio Pharma (Suzhou) Co's Revenue for the six months ended in Dec. 2025 was HK$0.00 Mil. Therefore, Longbio Pharma (Suzhou) Co's EBITDA margin for the quarter that ended in Dec. 2025 was 0.00%.

Longbio Pharma (Suzhou) Co  (HKSE:01779) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.

Longbio Pharma (Suzhou) Co EBITDA Margin % Related Terms

Longbio Pharma (Suzhou) Co EBITDA Margin % Historical Data

* Premium members only.

The historical data trend for Longbio Pharma (Suzhou) Co's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Longbio Pharma (Suzhou) Co EBITDA Margin % Chart

Longbio Pharma (Suzhou) Co Annual Data
Trend Dec24 Dec25
EBITDA Margin %
0.00 0.00

Longbio Pharma (Suzhou) Co Semi-Annual Data
Dec24 Dec25
EBITDA Margin % 0.00 0.00

HKSE:01779 vs : EBITDA Margin % Comparison

For the Biotechnology subindustry, Longbio Pharma (Suzhou) Co's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Longbio Pharma (Suzhou) Co EBITDA Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Longbio Pharma (Suzhou) Co's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Longbio Pharma (Suzhou) Co's EBITDA Margin % falls into.


HKSE:01779
10GF Score
Longbio Pharma (Suzhou) Co Ltd HKSE:01779
EBITDA Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Longbio Pharma (Suzhou) Co EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Longbio Pharma (Suzhou) Co's EBITDA Margin % for the fiscal year that ended in Dec. 2025 is calculated as

EBITDA Margin %=EBITDA (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-166.949/0
= %

Longbio Pharma (Suzhou) Co's EBITDA Margin % for the quarter that ended in Dec. 2025 is calculated as

EBITDA Margin %=EBITDA (Q: Dec. 2025 )/Revenue (Q: Dec. 2025 )
=-166.949/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBITDA Margin % →
What does a EBITDA Margin % of 0.00% mean?
Longbio Pharma (Suzhou) Co (HKSE:01779) has a EBITDA Margin % of 0.00% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Longbio Pharma (Suzhou) Co and its competitors. According to the industry distribution chart, Longbio Pharma (Suzhou) Co ranks #999999 out of 945 companies in the Biotechnology industry.
Is Longbio Pharma (Suzhou) Co's EBITDA Margin % too high?
Longbio Pharma (Suzhou) Co's current EBITDA Margin % is 0.00%. Based on the distribution chart, Longbio Pharma (Suzhou) Co ranks #999999 out of 945 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Longbio Pharma (Suzhou) Co has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does Longbio Pharma (Suzhou) Co's EBITDA Margin % compare to ?
According to the Biotechnology industry distribution chart, Longbio Pharma (Suzhou) Co ranks #999999 out of 945 companies for EBITDA Margin %. This places Longbio Pharma (Suzhou) Co in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Longbio Pharma (Suzhou) Co and its competitors. Longbio Pharma (Suzhou) Co's current EBITDA Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Longbio Pharma (Suzhou) Co stock overvalued right now?
Longbio Pharma (Suzhou) Co (HKSE:01779) has a current EBITDA Margin % of 0.00%. The current EBITDA Margin % is 0.00%. Longbio Pharma (Suzhou) Co's overall GF Score™ is 10/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Longbio Pharma (Suzhou) Co (HKSE:01779), the current EBITDA Margin % is 0.00% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Longbio Pharma (Suzhou) Co Business Description

Comparable Companies
Address No. 128 Yinhe Road, Dongnan Subdistrict, 5th Floor, Building F, Area A, Changshu City, Jiangsu Province, Suzhou, CHN
Longbio Pharma (Suzhou) Co Ltd is a clinical-stage biotechnology company. The company and its subsidiaries are principally engaged in the research, development, manufacture and commercialisation of pharmaceutical products in the People's Republic of China (the PRC). It has developed a comprehensive product pipeline for biologic treatments targeting rhinology, dermatology, respiratory, hematology, nephrology and other autoimmune diseases, targeting allergic and autoimmune diseases. Its pipeline includes LP-003, LP-00A, LP-005, LP-00C, and LP-00D.
10GF Score

Get the complete analysis for HKSE:01779

EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$157.20
Price